Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()

P001

Comparison of in vivo T cell homing to the inflamed gut with the etrolizumab surrogate antibody FIB504 and vedolizumab in a humanised mouse model

Year: 2016
Authors:

S. Zundler*, A. Fischer, R. Atreya, C. Neufert, I. Atreya, M. F. Neurath

University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany

P002

Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn’s sisease (CD) model

Year: 2016
Authors:

A. Grandi, I. Zini, M. Tognolini, V. Ballabeni, E. Barocelli, S. Bertoni*

University of Parma, Department of Pharmacy, Parma, Italy

P003

Activation of endoplasmic reticulum stress in the intestinal mucosa of Crohn’s disease patients

Year: 2016
Authors:

A. Coope*1, J. D. Botezelli2, M. L. S. Ayrizono1, L. A. Velloso3, 
R. F. Leal1

1University of Campinas, Coloproctology Unit, Surgery Department, Campinas, Brazil, 2University of Campinas, Campinas, Brazil, 3University of Campinas, Laboratory of Cell Signalling, Internal Medicine Department, Campinas, Brazil

P004

Exon-level microarrays identify alternative splicing for ICAM3 in Crohn’s disease

Year: 2016
Authors:

S. Verstockt*1, M. Vancamelbeke2, B. Verstockt2, F. Schuit3, M. Ferrante2, S. Vermeire2, I. Cleynen1, I. Arijs2

1KU Leuven, Department of Human Genetics, Leuven, Belgium, 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders, Leuven, Belgium, 3KU Leuven, Department of Cellular and Molecular Medicine, Gene Expression Unit, Leuven, Belgium

P005

Variability in Vedolizumab Exposure between Patients with Inflammatory Bowel Disease

Year: 2016
Authors:

A. Gils1, E. Dreesen*1, M. Peeters1, E. Brouwers1, M. Ferrante2, G. Van Assche2, S. Vermeire2

1KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2KU Leuven, P.O. Box 7003, Department of Clinical and Experimental Medicine, Leuven, Belgium

P006

Correlation of small intestinal permeability, faecal calprotectin and barrier genes in multiple-affected families with inflammatory bowel disease

Year: 2016
Authors:

M. Vancamelbeke*1, V. Ballet1, A. Luypaerts1, T. Vanuytsel1, M. Ferrante1, R. Farré1, K. Verbeke1, S. Vermeire1, I. Cleynen2

1University Hospitals Leuven - KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2KU Leuven, Department of Human Genetics, Leuven, Belgium

P007

IL-36 α expression is elevated in ulcerative colitis and promotes colonic inflammation

Year: 2016
Authors:

S. E. Russell1, 2, R. M. Horan1, 2, A. M. Stefanska1, 2, A. Carey1, 2, 
G. Leon2, M. Aguilera3, D. Statovci3, T. Moran2, P. G. Fallon2, F. Shanahan3, E. K. Brint4, S. Melgar*3, S. Hussey2, 5, P. T. Walsh1, 2

1Trinity College Dublin, Dublin, Ireland, 2National Children’s Research Centre, Our Lady’s Children Hospital, Dublin, Ireland, 3University College Cork, APC Microbiome Institute, Cork, Ireland, 4University College Cork, Department of Pathology, Cork, Ireland, 5University College Dublin, Academic Centre for Paediatric Research, Dublin, Ireland

P008

Targeting of TSLP by miR-31 may play an important role in mucosal healing, in ulcerative colitis.

Year: 2016
Authors:

S. Whiteoak*1, 2, A. Claridge1, 3, T. Sanchez-Elsner*1, J. F. Cummings2

1University of Southampton, Clinical and Experimental Sciences, Southampton, United Kingdom, 2University of Southampton, Department of Gastroenterology, Southampton, United Kingdom, 3Great Western Hospitals NHS Foundation Trust, Department of Gastroenterology, Swindon, United Kingdom

P009

Lipid biomarkers to diagnose Crohn’s disease using metabonomic profiling approach in serum and faeces.

Year: 2016
Authors:

N. S. Ding*1, 2, M. Sarafian1, 2, R. Misra1, P. Hendy1, L. Penez1, E. Holmes2, A. Hart1

1St Mark’s Hospital, IBD, London, United Kingdom, 2Imperial College London, Department of Surgery and Cancer, London, United Kingdom

1Philip Morris International Research Laboratories, Department of Reduced-Risk Products, Singapore, Singapore 2Philip Morris International R&D, Department of Reduced-Risk Products, Neuchatel, Switzerland

P010

Effects of cigarette smoke on the DSS-induced colitis model in C57Bl/6 mice

Year: 2017
Source:

1Philip Morris International Research Laboratories, Department of Reduced-Risk Products, Singapore, Singapore 2Philip Morris International R&D, Department of Reduced-Risk Products, Neuchatel, Switzerland

Authors:

Phillips B.1, Lo Sasso G.*2, Talikka M.2, Veljkovic E.1, Martin F.2, Elamin A.2, Guedj E.2, Ivanov N.2, Peitsch M.2, Hoeng J.2

P010

Infliximab skews macrophages towards an IL10-high/IL12p40-low phenotype in an Fc region dependent manner

Year: 2016
Authors:

F. Bloemendaal*1, M. Wildenberg1, A. Levin1, P. Koelink1, A.C. Vos2, G. D’Haens1, G. van den Brink1

1Academic Medical Centre, Gastroenterology, Amsterdam, Netherlands, 2Leiden University Medical Centre, Gastroenterology, Leiden, Netherlands

P011

Distinct inflammatory signatures in primary sclerosing cholangitis associated with inflammatory bowel disease

Year: 2016
Authors:

A. Gwela1, P. Siddhanathi1, R. W. Chapman1, C. Arancibia1, S. P .L. Travis1, F. Powrie2, A. Geremia*1

1John Radcliffe Hospital, Department of Translational Gastroenterology, Oxford, United Kingdom, 2University of Oxford, Kennedy Institute for Rheumatology, Oxford, United Kingdom

1Kazan State Medical University, Kazan, Russian Federation 2Kazan (Volga region) Federal University, Kazan, Russian Federation 3Kazan State Medical Academy, Kazan, Russian Federation 4Republican Clinical Hospital, Kazan, Russian Federation

P011

Evaluation the intestinal barrier function patients with inflammatory bowel disease

Year: 2017
Source:

1Kazan State Medical University, Kazan, Russian Federation 2Kazan (Volga region) Federal University, Kazan, Russian Federation 3Kazan State Medical Academy, Kazan, Russian Federation 4Republican Clinical Hospital, Kazan, Russian Federation

Authors:

Abdulganieva D.*1, Mukhametova D.1, Koshkin S.2, Zinkevich O.3, Saphina N.3, Abdulkhakov S.1,2, Odintsova A.4, Koporulina M.3

P012

MAIT cell activation reflects mucosal inflammation in ulcerative colitis

Year: 2016
Authors:

K. Haga*1, A. Chiba2, T. Shibuya1, T. Osada1, D. Ishikawa1, T. Kodani1, O. Nomura1, S. Watanabe1, S. Miyake2

1Juntendo University, Department of Gastroenterology, Tokyo, Japan, 2Juntendo University, Department of Immunology, Tokyo, Japan

1Graduate School of Medicine, Kyoto University, Gastroenterology and Hepatology, Kyoto, Japan 2Institute of Development, Aging and Cancer, Tohoku University, Molecular and Cellular Biology, Sendai, Japan 3Sapporo Medical University School of Medicine, Gastroenterology and Hepatology, Sapporo, Japan

P012

Ral activation exacerbates colonic inflammation through the impairment of intestinal barrier function in experimental murine colitis

Year: 2017
Source:

1Graduate School of Medicine, Kyoto University, Gastroenterology and Hepatology, Kyoto, Japan 2Institute of Development, Aging and Cancer, Tohoku University, Molecular and Cellular Biology, Sendai, Japan 3Sapporo Medical University School of Medicine, Gastroenterology and Hepatology, Sapporo, Japan

Authors:

Minami N.*1, Matsuura M.1, Yamamoto S.1, Honzawa Y.1, Yamada S.1, Koshikawa Y.1, Okabe M.1, Seno H.1, Horiuchi H.2, Nakase H.3

P013

Automated image analysis in the diagnosis of microscopic colitis: validation and implications for diagnosis and research

Year: 2016
Authors:

P. J. H. Engel*1, 2, L. K. Munck2, 3, U. H. Engel4, S. Holck4, A.-M. Kanstrup-Fiehn1, M. Kristensson5

1Roskilde Hospital, Department of Pathology, Roskilde, Denmark, 2University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark, 3Koege Sygehus, Department of Gastroenterology, Koege, Denmark, 4Copenhagen University Hospital, Department of Pathology, Hvidovre, Denmark, 5Visiopharm, Hoersholm, Denmark

University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

P013

Decreased fibrogenesis in CH25H knockout mice in a mouse model of intestinal fibrosis

Year: 2017
Source:

University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

Authors:

Raselli T., Wyss A., Gonzalez Alvarado M.N., Mamie C., Rogler G., Hausmann M., Misselwitz B.

1Rijnstate Hospital, IBD Centre, Gastroenterology and Hepatology, Arnhem, Netherlands 2Rijnstate Hospital, Microbiology and Immunology, Arnhem, Netherlands

P014

Mucosal lymphocyte subsets in ulcerative colitis at diagnosis and during follow-up

Year: 2017
Source:

1Rijnstate Hospital, IBD Centre, Gastroenterology and Hepatology, Arnhem, Netherlands 2Rijnstate Hospital, Microbiology and Immunology, Arnhem, Netherlands

Authors:

Smids C.*1, Horjus Talabur Horje C.1, Groenen M.1, van Koolwijk E.2, Wahab P.1, van Lochem E.2

P014

Tofacitinib and a selective Janus kinase 1 inhibitor are equally potent in suppressing human macrophage function and T-cell proliferation

Year: 2016
Authors:

L. De Vries*1, 2, M. Wildenberg2, V. Ludbrook3, G. D’Haens1, 
W. De Jonge2

1Academic Medical Centre (AMC), Gastroenterology & Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, 3GlaxoSmithKline, ImmunoInflammation Therapy Area, Stevenage, United Kingdom

P015

Interaction between enteric glia and myeloid cells as critical players in intestinal immune homeostasis.

Year: 2016
Authors:

G. Goverse*, M. Stakenborg, M. van Winge, E. Labeeuw, G. Farro, M. Hao, P. J. Gomez Pinilla, G. Boeckxstaens, G. Matteoli

KU Leuven, P.O. Box 701, Department of Clinical and Experimental Medicine, Leuven, Belgium

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()